drugset / Trial / NCT03379493
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Phase 1
Terminated
4 enrolled
Eureka Therapeutics Inc.
Duke Clinical Research Institute · collabDuke University · collab
SequentialOpen-labelTreatment
Summary
This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years of age with relapsed or refractory CD19+ Non-Hodgkin's lymphoma.
Timeline
- Start
- 2018-04-04
- Primary completion
- 2018-12-23
- Completion
- 2019-01-30
Outcome
Outcome not reported
Stopped: “Sponsor's Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET190L1 ARTEMIS™ T cells | Cell therapy | — | Intravenous |